Please login to the form below

Not currently logged in
Email:
Password:

Achillion

This page shows the latest Achillion news and features for those working in and with pharma, biotech and healthcare.

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion

Additional shares will be tied to various milestones. Alexion has added to its rare blood disorder pipeline with a $930m agreement to buy smaller biotech Achillion Pharma. ... The $6.30-per-share offer is a 73% premium on Achillion’s closing share

Latest news

  • J&J buys firm seeking hepatitis B cure J&J buys firm seeking hepatitis B cure

    J&J is also continuing to research new HCV therapies, and earlier this year paid up to $1.1bn for the rights to Achillion Pharmaceuticals' pipeline of drugs, headed by

  • J&J signs $1bn deal with Achillion for hepatitis C therapies J&J signs $1bn deal with Achillion for hepatitis C therapies

    Will license three candidates from Achillion Pharma.  . Johnson &Johnson (J&J) has fleshed outs its portfolio of hepatitis C virus drugs, licensing three candidates from Achillion Pharma in a deal valued ... The agreement - which sits alongside a $225m

  • Gilead and Achillion see 100% success rate in hep C trial Gilead and Achillion see 100% success rate in hep C trial

    Gilead and Achillion have posted impressive clinical study results for a new all-oral combination hepatitis C treatment. . ... be an all-Achillion regimen, predicted to hit the US market by the end of the decade.

  • Hepatitis C therapies: dawn of a new age Hepatitis C therapies: dawn of a new age

    Achillion Pharmaceuticals has DAAs sovaprevir, neceprevir and ACH 3102 in the works, Idenix and Janssen are collaborating on samatasvir and TMC 647055, and phase 2 development of JNJ 56914845 (Janssen) is

  • FDA forces Achillion to delay hepatitis C programme FDA forces Achillion to delay hepatitis C programme

    Abnormal liver functions detected in some patients taking sovaprevir. Achillion's development of its hepatitis C treatment sovaprevir will be delayed after reports of abnormal liver functions in some patients caused ... trials. According to Achillion,

More from news
Approximately 4 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Managing value: Why early asset development and commercialisation are important Managing value: Why early asset development and commercialisation are important

    For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of

  • Pharma deals in May 2015 Pharma deals in May 2015

    Clearly a very successful and creative partnership! Choosing to opt for partnership over an acquisition, J&J closed a multiple licence with Achillion to build on its hepatitis C portfolio. ... 1, 300. Achillion/ J&J. Licence. Joint development and

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics